Breast cancer: major risk factors and recent developments in treatment.

Breast cancer is the most common in women worldwide, with some 5-10% of all cases due to inherited mutations of BRCA1 and BRCA2 genes. Obesity, hormone therapy and use of alcohol are possible causes and over-expression of leptin in adipose tissue may also play a role. Normally surgery, radiation therapy and chemotherapy allow a good prognosis where screening measures are in place. New hope in treatment measures include adjuvant therapy, neoadjuvant therapy, and introduction of mono-clonal antibodies and enzyme inhibitors.

[1]  Pamela Shaw.  Ross and Wilson Anatomy and Physiology in Health and Illness – Twelfth edition Waugh Anne and Grant Allison Ross and Wilson Anatomy and Physiology in Health and Illness – Twelfth edition 528pp £31.99 Elsevier 978 0 7020 5325 2 0702053252 , 2014 .

[2]  Yu Fan,et al.  Fulvestrant 250mg versus Anastrozole 1 mg in the Treatment of Advanced Breast Cancer: a Meta-Analysis of Randomized Controlled Trials , 2014 .

[3]  M. Balasubramanian,et al.  D-pinitol promotes apoptosis in MCF-7 cells via induction of p53 and Bax and inhibition of Bcl-2 and NF-κB. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[4]  I. Çiçin,et al.  Medical treatment of breast cancer bone metastasis: from bisphosphonates to targeted drugs. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[5]  G. Curigliano,et al.  Expert perspectives on biosimilar monoclonal antibodies in breast cancer , 2014, Breast Cancer Research and Treatment.

[6]  Yu Fan,et al.  Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[7]  Yan Zhang,et al.  MiR-886-5p inhibition inhibits growth and induces apoptosis of MCF7 cells. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[8]  M. Louisa,et al.  In vitro modulation of P-glycoprotein, MRP-1 and BCRP expression by mangiferin in doxorubicin-treated MCF-7 cells. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[9]  Paloma H. Giangrande,et al.  Current progress on aptamer-targeted oligonucleotide therapeutics. , 2013, Therapeutic delivery.

[10]  F. Vera-Badillo,et al.  Fulvestrant for advanced breast cancer: a meta-analysis. , 2013, Cancer treatment reviews.

[11]  F. Marincola,et al.  Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions , 2013, Expert review of vaccines.

[12]  S. Duffy,et al.  Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer , 2013, Breast Cancer Research.

[13]  T. Dörk,et al.  Hereditary breast cancer: ever more pieces to the polygenic puzzle , 2013, Hereditary Cancer in Clinical Practice.

[14]  R. Finn,et al.  Current approaches and future directions in the treatment of HER2-positive breast cancer. , 2013, Cancer treatment reviews.

[15]  A. Harris,et al.  New strategies for targeting the hypoxic tumour microenvironment in breast cancer. , 2013, Cancer treatment reviews.

[16]  C. Sotiriou,et al.  Pertuzumab: new hope for patients with HER2-positive breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  H. Soliman.  Immunotherapy strategies in the treatment of breast cancer. , 2013, Cancer control : journal of the Moffitt Cancer Center.

[18]  Patrick Lindsey,et al.  A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer , 2013, Breast Cancer Research.

[19]  R. Nahta.  New developments in the treatment of HER2-positive breast cancer. , 2012, Breast cancer.

[20]  S. Vyas,et al.  Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy. , 2012, Molecular pharmaceutics.

[21]  R. Nahta.  New developments in the treatment of HER 2-positive breast cancer , 2012 .

[22]  F. Marincola,et al.  A signature of immune function genes associated with recurrence-free survival in breast cancer patients , 2012, Breast Cancer Research and Treatment.

[23]  Nan Wang,et al.  Monoclonal antibodies in cancer therapy , 2011 .

[24]  Patrick Neven,et al.  Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. , 2011, The Lancet. Oncology.

[25]  Early Breast Cancer Trialists' Collaborative Group.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[26]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.

[27]  M. Ellis,et al.  Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool , 2010, British Journal of Cancer.

[28]  K. Jirström,et al.  Differential expression of cytoplasmic and stromal β-arrestin-1 is associated with separate aspects of tumor behavior in breast cancer , 2009, Breast Cancer Research.

[29]  Achim Rody,et al.  T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers , 2009, Breast Cancer Research.

[30]  R. O'Regan,et al.  Adjuvant hormonal therapy for early-stage breast cancer. , 2008, Cancer treatment and research.

[31]  M. Rossing,et al.  Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients , 2007, Breast Cancer Research.

[32]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[33]  E. Jaffee,et al.  Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. , 2005, Cancer research.

[34]  C. Osborne,et al.  Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma , 2005, Cancer.

[35]  Y. Yarden,et al.  Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Riethmüller,et al.  Monoclonal antibodies in cancer therapy , 2004, Springer Seminars in Immunopathology.

[37]  C. Boni,et al.  Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Y. Miyoshi,et al.  Adjuvant hormonal therapy , 2002, Breast cancer.

[39]  P. Schwarzenberger,et al.  Early stage breast cancer. , 1997, Oncology reports.

[40]  H. Tsuda,et al.  A case of dermatofibrosarcoma protuberans in the skin over the breast , 1997, Breast cancer.

[41]  J. Bausch,et al.  Monoclonal antibodies. , 1990, Bioprocess technology.